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Objectives. Haemophilia A is a congenital disorder of coagulation that mainly affects males and causes a considerable use of
resources, especially when hemophilic patients are treated with prophylaxis. The aim of the present review was to discuss and
appraise the methodological aspects and results of published economic evaluations of haemophilia A treatments in the last
decade. Methods. The literature search, performed by consulting four engines, covered studies published between 2002 and 2014.
Full economic evaluations published in English language were identified and included in the review. A quality assessment of
the studies was also carried out based on Drummond’s checklist. Results. After careful evaluations of the identified records, 5
studies were reviewed. Primary and secondary prophylaxis resulted cost-effective compared to on-demand therapy: the ICER of
primary prophylaxis ranged from C40.236 to C59.315/QALY gained, while the ICER of secondary prophylaxis was C40.229/QALY
gained. Furthermore, 60% were high quality and 40% were medium quality studies. Conclusions. The review underlines the cost-
effectiveness of prophylaxis versus on-demand treatment and the different methodological approaches applied. Further economic
evaluations are required with models that reflect the clinical reality and consumption of resources in each country.
1. Introduction
Haemophilia A is a congenital disorder of coagulation that
mainly affects males; the prevalence in the Italian population
was 6.2/100.000 inhabitants in 2012 (95%CI 6.0–6.4) and
12.7/100.000 inhabitants (95%CI 12.3–13.1) among the Italian
males [1]. As other chronic diseases, haemophilia has high
economic burden, especially when patients are treated with
prophylaxis. This is mainly due to the complex therapy
management process that involves expensive treatments. In
particular, as confirmed by the available scientific literature,
haemophilia A is one of the most expensive diseases because
of the required lifetime treatment and the management of
the related adverse effects and complications, especially when
patients develop factor VIII inhibitors [2–5]. In addition,
indirect costs, usually expressed in terms of considerable loss
of productivity for the society, should be taken into account
[6, 7]. High healthcare costs are due to the continuous
factor VIII (FVIII) infusions therapy that people affected by
haemophilia A need for the management and the prevention
of bleedings and to reduce the risk of complications, such
as flexion contractures, joint arthritis/arthropathy, chronic
pain, muscle atrophy, compartment syndrome, neurologic
impairment.
Replacement therapy is the main treatment for haemo-
philia A; it consists in infusions aimed at replacing the
missing or faulty clotting factor in the blood stream. In parti-
cular, infusions could be injected either on-demand or on
regular basis (prophylaxis). According to the scientific litera-
ture, prophylaxis is the first choice therapy, especially for
children with severe haemophilia A [8].
Several economic evaluations have been conducted to
compare on-demand versus prophylactic treatment in terms
of cost-effectiveness and/or cost-utility.
The current paper is a systematic review of full eco-
nomic evaluations (cost-effectiveness and cost-utility anal-
yses), conducted in different countries. The objective of
this review was to discuss and appraise the methodological
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Figure 1: Flow chart of the selection process.
aspects and results of published economic evaluations of
haemophilia A available treatments from January 2002 to
November 2014.
2. Materials and Methods
2.1. Identification of Relevant Studies. The literature search,
which covered studies published from 1st January 2002 until
3rd November 2014, was performed by consulting PubMed
and Scopus engines. Further researchwas carried out through
Google and Google scholar. Search terms were used as
follows:
(1) (cost effectiveness) AND (haemophilia prophylaxis
versus on-demand);
(2) (cost-utility) AND (haemophilia prophylaxis versus
on-demand).
The only limit set for all search engines was the publication
date. Search criteria are summarized in Figure 1. In the
selection process, abstracts were initially read independently
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by two researchers to identify the potentially eligible full text
papers, which were then retrieved and assessed in order to
decide on the final inclusion. Full economic evaluations (cost-
effectiveness and cost-utility analysis) published in English
language were identified and included in the review.
Full economic evaluation is the comparative analysis of
alternative courses of action in terms of both costs (resource
use) and consequences (outcomes, effects) [9]. Studies on the
use of healthcare resources that do notmake explicit compar-
isons between alternative interventions in terms of both costs
(resource use) and consequences (effects) are considered as
partial economic evaluations and include cost analyses, cost-
description studies, and cost-outcome descriptions [10].
Consequently, partial economic evaluations that did not
meet the inclusion criteria above explained were excluded.
Reviews, duplicate articles, and studies without available full
text were also eliminated.
For comparison of results on haemophilia treatment,
studies considering inhibitor patients were also excluded
since the presence of inhibitors requires different treatment
modality associated with higher health care cost and reduced
overall efficacy compared to replacement of the deficient
factor. Furthermore, all costs are express in Euro and, when
necessary, they were converted to Euro by using the Euro
foreign exchange reference rates as at November 2014.
2.2. Quality Assessment and Data Extraction. A quality
assessment of the included studies was carried out, based
on the British Medical Journal (BMJ) referees’ checklist
proposed by Drummond and Jefferson [11] and modified
by La Torre et al., weighting-median score for each item by
different experts [12].
Drummond’s checklist is composed of 35 items divided
into 3 sections: study design, data collection and analysis,
and interpretation of results. To weight the items, a group of
experts attributed a score according to their importance. The
weighted scores assigned by the consensus to study design,
data collection and analysis, and interpretation of results were
26, 45, and 48, respectively (total score = 119). For each item
section, the maximum achievable score was as follows:
(1) study design (7 items), maximum global score = 26;
(2) data collection (14 items), maximum global score =
45;
(3) analysis and interpretation of results (14 items), max-
imum global score = 48.
When the item was not applicable to the study, we reduced
the maximum global score from the relative weighted score
item.
Discrepancies between the two investigators were solved
by oral discussion and consensus with senior investigators
(GLT, WR). Each item was assigned with the median weight
attributed by the consensus, if applicable. Finally, we obtained
the global score summing up weights of each item. Studies
achieving a score above 90 were considered of high quality.
Two reviewers used a data collection form to inde-
pendently abstract data from the studies. The informa-
tion extracted is the following: reference with publica-
tion year, type of analyses, alternatives, country/perspective,
patients/time horizon, effectiveness measurement/cost mea-
surement, and results. The reviewers discussed any discrep-
ancies in their results to reach an agreement. The character-
istics of each study are depicted in Table 1.
The review results are presented according to the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) statement [13].
3. Results
3.1. Literature Search. The literature search, using the two
strings above mentioned, brought out 28 potentially useful
articles:
(i) 11 for PubMed search;
(ii) 14 for Scopus search;
(iii) 3 additional records for Google and Google scholar
search.
The articles were screened based on title and abstract and,
after the removal of duplicate records and nonrelevant arti-
cles, five studies were included in the review. The excluded
studies were 15 duplicate records, 1 review article, 2 articles
considering haemophilia patients with inhibitors, and 5
partial economic analyses (Figure 1).
Most economic evaluations included in the review com-
pared costs and clinical outcomes associated with the infu-
sion of FVIII in prophylaxis and on-demand treatment.
Moreover, all studies included a cost-utility analysis in which
quality-adjusted life-years (QALYs) are used as measures of
health effects [14–18].The analyses were conducted mainly in
Europe. In particular, two studies have been conducted in the
United Kingdom (UK) [14, 15], one in Canada [16], one in
Germany/Sweden/UK/the Netherlands [17], and one in Italy
[18].
3.2. Review Results. The study by Miners and colleagues
(2002) was a cost-utility analysis, conducted in UK from
the societal perspective [14]. Two treatment options were
compared: primary prophylaxis and on-demand treatment.
The sample included in the analysis was a hypothetical cohort
of patients with severe haemophilia A or haemophilia B and
von Willebrand disease. Data on clinical effects and costs
of treatments were combined in the Markov model. As the
study was conducted from the societal point of view, indirect
costs, expressed in terms of school/work days lost, were also
considered in addition to direct costs. The analysis showed
that primary prophylaxis, compared with on-demand treat-
ment, was cost-effective.The baseline analysis evidenced that
the incremental cost-effectiveness ratio (ICER) was m46.500
(C59.315) per QALY gained, for individuals receiving FVIII
and factor IX (FIX).
In 2009, Miners modified the 2002 model [14], by
updating the previously published data [15]. The study was
conducted from the perspective of the National Health
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Service (NHS). In the study published in 2002 [14], only costs
were discounted at an annual discount rate of 6%, while in
the updated study by Miners [15] an annual discount rate of
3.5% per annum has been applied to both costs and benefits.
In this study, there was a gap between the utility gained
by patients treated with prophylaxis (0.87) and the utility
gained by patient treated on demand (0.66). In the 2009
study, ICER per QALY—in the baseline analysis—was lower
(m38.000; C48.469) than the value of the study published in
2002 (m46.500; C59.315). This difference could depend on the
price of FVIII and on the frequency of infusions. However,
the sensitivity analysis showed that the results were very
sensitive to
(i) unit cost of clotting FVIII;
(ii) discount rate;
(iii) bleeding frequency;
(iv) utility assumptions.
The study conducted in Canada by Risebrough et al. [16] eval-
uated the cost-utility profile of escalading-dose (EscDose)
compared to on-demand treatment and primary prophylaxis
with EscDose. A hypothetical cohort of male patients, aged
between 1 and 6 years with severe haemophilia A, was
considered. As the analysis was conducted from the societal
point of view, indirect costs, expressed in terms of working
days lost by parents to assist children, were also included.
A Markov model was developed for the economic analy-
sis, with health states based on the number of “target joints”
involved. The results were expressed in terms of Canadian$
(Can$) per QALY.The incremental cost per QALY gained for
EscDose compared with primary prophylaxis was more than
Can$ 1.000.000 (C698.300 (Exchange rate Can$ 1 = C0.6983
[updated to November 4, 2014])) per QALY gained. On the
other hand, by comparing on demand to EscDose, the ICER
was Can$ 542.938 (C379.134 (exchange rate Can$ 1 = C0.6983
[updated to November 4, 2014])) per QALY gained.
The sensitivity analysis showed that the results are sensi-
tive to the price of the clotting FVIII and to the number of
“target joints” involved. In conclusion, the analysis demon-
strated that prophylaxis significantly improved the quality of
life of children affected by severe haemophilia A.The study by
Lippert et al. [17] was conducted in several European coun-
tries (Germany, Sweden, UK, andThe Netherlands) from the
third-party payers’ perspective. A full economic evaluation
was performed to estimate the cost-effectiveness of on-
demand versus prophylactic therapy.The sample consisted of
516 patients, with severe haemophilia A and haemophilia B,
without clotting factor inhibitors (VIII/IX), who aged more
than 14 years.
The analysis demonstrated that patients receiving pro-
phylaxis were subject to less bleeding episodes than those
who were treated on demand. In this analysis, the results
were very different from those of the studies reported above
[14–16]. In particular, in the group of patients who aged less
than 30 years and were HIV positive, the ICER ranged from
C1.2million/QALY in Germany to C1.72million/QALY in
UK.
On the other hand, in the group of patients who aged
less than 30 years and were HIV negative, the ICER was
C2.21million/QALY and C3.10million/QALY in Germany
and in UK, respectively.
Finally, in the group of patients aged more than 30 years
old and HIV-negative, ICER ranged from C4.77million/
QALY in Germany to C5.7million/QALY in Sweden and in
the UK.
The study conducted by Colombo et al. [18] was a cost-
utility analysis based on the model developed by Miners et
al. in 2002 [14]. TheMarkov model was adapted to the Italian
context by replacing some clinical and economic parameters.
The analysis was performed from the perspective of the
NHS. Four alternatives were compared: primary prophylaxis,
secondary prophylaxis, hybrid regimen (primary prophylaxis
followed by on-demand treatment), and on-demand treat-
ment. According to Miners’ et al. study, published in 2002
[14], a discount rate of 6% was applied to all costs. The
analysis showed that the primary and secondary prophylaxes
were cost-effective when compared to on-demand treatment
(ICER = C40.236/QALY and C40.229/QALY, resp.). The
hybrid strategy (prophylaxis therapy followed by on-demand
therapy) was less cost-effective than primary and secondary
prophylaxes (ICER = C119.134).
Table 1 depicts and summarizes the main characteristics
of the studies reviewed.
3.3. Results of the Quality Assessment. In all included studies
[14–18], the research question (item 1), its economic impor-
tance (item 2), the analysis point of view (item 3), and the
form of economic evaluation (item 6) were clearly stated. All
studies, except one [18], clearly described the rationale for
choosing the alternative programmes (item 4), the sources
of data effectiveness (item 8), the primary outcomes of
the economic evaluation (item 11), and currency and price
data (item 18). Moreover, all analysis reported appropriate
conclusions (item 34) and caveats (item 35) by giving a
satisfactory answer to the study question (item 33). In 3 out
of 5 analyses, the choice of the economic evaluation form
was justified (item 7) [15, 17, 18], while only one study [16]
reported the details of the subjects from whom evaluations
were obtained (item 13). All studies reported the methods to
evaluate health status and other benefits (item 12).
Despite the discount rates that were stated (item 23) in
most studies, except for Lippert et al. [17], only one of them
[15] justified the choice of the rates (item 24). In particular,
the studies by Colombo et al. [18] and Miners et al., 2002
[14], reported a discount rate of all cost at 6%, whilst Miners
2009 [15] discounted costs at 6% and benefits at 0%. Finally,
Risebrough et al. [16] reported a 3% rate for all cost and
QUALYs.
All economic evaluations gave details for inflation adjust-
ment or currency conversion (item 19) and model details
(item 20). In all studies, relevant alternatives were compared
(item 30), incremental analysis was reported (item 31), and
outcomes were presented both in aggregate and disaggregate
forms (item 32). Most studies (80%) reported costs and
resources separately (item 16) and all studies described the
methods followed to estimate them (item 17).
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Table 2: Results of the quality assessment with scores∗.
Economic
evaluations analyzed
Miners et al., 2002
[14]
Lippert et al., 2005
[17]
Risebrough et al.,
2008 [16] Miners, 2009 [15]
Colombo et al., 2011
[18]
Study design
(maximum score 26) 26 23 26 23 19
Data collection
(maximum score 45) 34 28 39 29 29
Analysis and
interpretation of
results
(maximum score 48)
39 32 39 39 36
Total
(maximum score 119) 100 83 104 91 84
∗According to Drummond’s checklist modified by La Torre et al. [12].
Despite the fact that sensitivity analyses were reported in
all studies (item 27), only three of them [14–16] justified the
choice of the variables included (item 28).
Relative to the scores achieved in each section, in the
first section, the quality scores ranged between 19 [18] and
26 [14, 16]; in the second section, the maximum score of 39
was achieved by the study by Risebrough et al. [16] while the
minimum score of 28 was reached by Lippert et al. [17]. In
the third section, the scores ranged between 32 [17] and 39
[14–16] (Table 2). Therefore, highest scores were achieved in
the study design section while the worst was data collection
section.
Moreover, the overall score ranged between 83 [17] and
104 [16] (Table 2).The difference between the scores achieved
by the two studies conducted byMiners et al. [14, 15] depends
mainly on the lack of a valid justification about the choice
of the economic analysis form (first section) and the lack
of indirect benefits/productivity changes (second section).
These issues were included in the study published in 2002 [14]
but were not analysed in the updated evaluation [15].
According to Drummond’s checklist [11], modified by La
Torre et al. [12], 60% were high quality studies and 40% were
medium quality, mainly becausemethods and data collection
were not exhaustively described.
4. Discussion
The aim of this review was to examine the methodological
aspects and results of published economic evaluations on
haemophilia A available treatments from 2002 to 2014.
The authors of the reviewed studies strongly agreed on
the fact that prophylaxis, compared to on-demand treatment,
achieves better health outcomes at additional costs, despite
the different methodological approaches.
The extreme variability among the results of the studies
is essentially due to several factors: first, the different time
horizon used in all the analyses, and, secondly, the discount
rate that can affect the results, especially if it is not applied to
both costs and benefits. Other important factors that should
be considered are
(i) the method that follows collect data (i.e., trials and
cohort studies);
(ii) unit costs of clotting FVIII;
(iii) assumptions about utility.
In this regard, Lippert and colleagues’ results [17] should
be analysed as significantly different from those in other
studies. This depends mainly on the short time horizon that
is not sufficient to take into account long-term effects. In a
time horizon of only one year applied in their analysis, the
QUALYs gained are surely minimal (from 0.0187 to 0.0586
QALY for the different cases) with high ICERs (C1.2 and
5.7million/QUALY) compared to a lifetime model [17].
In the Italian context, the analysis carried out by Capri
and Ricciardi in 2011 as part of a Health-technology assess-
ment (HTA) [19] also underlines the cost-effectiveness of
primary prophylaxis with FVIII compared to on-demand
therapy. They found an ICER of C35.036 in a time horizon
of 70 years. The ICER obtained by Capri and Ricciardi
[19] is less than C40.229 achieved by Colombo et al. for
primary prophylaxis in a lifetime model [18]. Both studies
were conducted from the perspective of the Italian National
Health System (NHS) in the same year and due to lack of
suitable Italian data, the assumptions about utilities were
derived fromMiners et al. 1999 [20].
The results of the two Italian analyses differ principally
for the unit cost of factor therapy (C0.75 for Capri and
Ricciardi versus C0.68 for Colombo et al.), the time horizon,
and for the difference in FVIII half-life which influences the
quantity of clotting factor required. Hence, besides the cost
of treatment, an economic evaluation should also take into
account the immunogenic profile of the factor therapy, which
was not considered in the study by Colombo et al. [18].
The only non-European economic evaluation reviewed is
the Canadian study [16], which compared standard prophy-
laxis and escalating-dose versus on-demand therapy over 5
years. The ICERs found (C379.134 and C698.300) are almost
a tenth of the value reported by European studies. Also
in this case, the variability of the results can be explained
with the different time horizon, treatment regiments, and
quantity/costs of clotting factor considered.
The studies reviewed can be also compared, for
some aspects, to the recent cost-utility analysis of severe
haemophilia A treatment over a lifetime horizon performed
by Farrugia et al. 2013 [21]. Their model reflects the
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importance of inhibitor development and included the use
of low-dose tolerization protocol in the first years of life as
soon as a bleeding tendency manifests and then changed to
the childhood and adult pharmacokinetic schedules. This
approach is associated with a low probability of high cost
inhibitor therapy as reported by Kurnik et al. 2010 [22] and
results in the dominance of prophylaxis over on-demand
treatment.
The model by Farrugia et al. [21] was influenced mainly
by the dosage/cost of FVIII and inhibitor development.
In particular, prophylaxis was dominant over on-demand
treatment in UK due to the low cost of FVIII. In the USA
case, prophylaxis has a higher cost over on-demand therapy
due to the high cost of FVIII, but the ICER of $68.000
(C54.339 (Exchange rate $1 = C0.7987 [Updated toNovember
4, 2014])) is still within the range that is considered justified
and is similar to European values [14, 15, 18].
Finally, in Sweden, the ICER was SEK 879.168 (C94.598
(Exchange rate 1SEK = C 0.1076 [updated to November 4,
2014])) over a life span [21], which is clearly less than the
findings by Lippert et al. [17] of 5.7million/QUALY in a year
for patients with severe haemophilia.
According to the Guidelines for haemophilia, one option
for the treatment of very young children is to start prophylaxis
once a week [23] and the initiation of prophylaxis from an
early age can obviate bleeding complications [6, 23–25].Thus,
themodel proposed by Farrugia et al. [21] has strong basis, but
more clinical evidence is needed to increase the significance
of the low-dose regimen since the assumptions were derived
from a pilot study and the optimal regimen remains to be
defined.
Considering the quality assessment, the less discussed
aspects in the reviewed studies (tackled in only one paper out
of 5) are the details of the subjects from whom health states
evaluations and justification about the choice of the discount
rate were obtained: aspects that are present in the work by
Farrugia et al. [21].
A limit of the present review is surely the period lim-
itation for the studies (2002–2014) that excludes analyses
performed in previous years. On the other hand, the spec-
ified period gave us the possibility to concentrate on the
results of recent publications. The reviewed articles were
then compared to other works, including the most recent.
A particular attention is also dedicated to the Italian setting,
considering the origin of most authors of the present work.
These aspects differentiate our review from the work by
Miners [26], which included cost-effectiveness, cost-benefit,
and cost-utility analysis up to 2012.
5. Conclusion
The reviewed studies highlight the undoubted benefits of
prophylaxis, as reported in the Guidelines for the Treatment
of Hemophilia [23]. Yet some aspects of the economic
models proposed might be further developed. Specifically,
full economic analysis of haemophilia treatment should also
consider the cost therapy in presence of inhibitors, which can
affect ICER significantly: these issues were not addressed in
the studies included in the review.
The recent work by Farrugia et al. [21] presents an
integrated clinical scenario compared to previous analyses
for a lifetime therapy [14, 15, 18]. The new model proposed
could be the response to the bleeding problems in the
increasing population of aged hemophiliacs, since early low-
dose prophylactic protocol decreases the inhibitor incidence
and bleeding complications, underlining the dominance of
prophylaxis over on-demand treatment.
In conclusion, the cost of treatment, inhibitor develop-
ment, and the immunogenic profile of the factor therapy
should be considered in economic analyses to obtain a model
that is closer to clinical reality, cost, and consumption of
resources in each country. In fact, in most of the evaluations,
assumptions are derived from the literature due to the lack
of current data, as in the Italian case. We suggest conducting
further economic evaluations in the Italian context in order
to provide clear and specific data for the NHS and to obtain
more accurate results for the treatment of haemophilia A.
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